ARTV
Artiva Biotherapeutics, Inc. NASDAQ Listed Jul 19, 2024$11.28
-2.17%
vs $11.53
Mkt Cap $551.5M
52w Low $2.22
73.6% of range
52w High $14.53
50d MA $9.51
200d MA $6.77
P/E (TTM)
—
EV/EBITDA
—
P/B
2.5x
Debt/Equity
0.1x
ROE
-76.3%
P/FCF
-3.6x
RSI (14)
65.50
ATR (14)
$0.89
Beta
1.48
50d MA
$9.51
200d MA
$6.77
Avg Volume
405.7K
Artiva Biotherapeutics, Inc., a clinical-stage biotechnology company, focuses on developing natural killer (NK) cell-based therapies for patients suffering from autoimmune diseases and cancers. The company's lead product candidate is AB-101, an off-the-shelf NK cell therapy for patients with autoimmune diseases and cancers, such as lupus nephritis, rheumatoid arthritis, pemphigus vulgaris, the anti-neutrophil cytoplasmic antibody-associated vasculitis subtypes granulomatosis with polyangiitis/microscopic polyangiitis, systemic lupus erythematosus, and B-cell-non-Hodgkin lymphoma. It also develops AB-201, an allogeneic anti- human epidermal growth factor receptor 2 chimeric antigen receptor (CAR)-NK cell product candidate; and AB-205, an allogeneic anti-CD5 CAR-NK cell product candidate. The company was incorporated in 2019 and is headquartered in San Diego, California.
CIK (SEC)
Phone
858 267 4467
5505 Morehouse Drive · San Diego, CA 92121 · US
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mar 10, 2026 | AMC | -0.87 | -0.84 | +3.4% | 6.08 | +0.7% | +17.3% | -5.3% | -8.4% | +0.0% | +2.3% | — |
| Nov 12, 2025 | AMC | -0.92 | -0.88 | +4.3% | 3.98 | +2.3% | -14.8% | -4.1% | +8.0% | +10.8% | -12.9% | — |
| Aug 6, 2025 | AMC | -0.84 | -0.87 | -3.6% | 2.87 | -2.8% | -8.0% | +4.5% | -7.2% | -3.5% | +8.1% | — |
| May 8, 2025 | AMC | -0.68 | -0.83 | -22.1% | 2.18 | -0.5% | -4.6% | +1.0% | -2.4% | -11.7% | +17.7% | — |
| Mar 25, 2025 | AMC | -0.71 | -0.66 | +7.0% | 3.99 | -2.0% | -8.8% | -2.7% | -10.7% | -5.1% | +0.0% | — |
| Nov 12, 2024 | AMC | -0.68 | -0.92 | -35.3% | 13.07 | +1.5% | -10.5% | -10.2% | -4.3% | +2.5% | +9.6% | — |
| Aug 29, 2024 | AMC | -4.40 | -22.00 | -400.0% | 11.30 | -3.9% | +2.1% | -4.6% | +3.4% | +4.7% | +0.9% | — |
| Jun 30, 2024 | AMC | — | -0.62 | — | — | — | — | — | — | — | — | — |
| Dec 31, 2023 | AMC | — | -0.30 | — | — | — | — | — | — | — | — | — |
| Sep 30, 2023 | AMC | — | 1.20 | — | — | — | — | — | — | — | — | — |
| Jun 30, 2023 | AMC | — | -0.90 | — | — | — | — | — | — | — | — | — |
| Mar 31, 2023 | AMC | — | -0.95 | — | — | — | — | — | — | — | — | — |
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mar 11 | Needham | Maintains | Buy → Buy | — | $6.08 | $6.12 | +0.7% | +17.3% | -5.3% | -8.4% | +0.0% | +2.3% |
| Nov 12 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $3.59 | $3.59 | +0.0% | +10.9% | -14.8% | -4.1% | +8.0% | +10.8% |
| Oct 17 | Needham | Maintains | Buy → Buy | — | $2.77 | $5.59 | +101.8% | +117.0% | -18.3% | -11.2% | +2.8% | +8.0% |
| Oct 17 | Wedbush | Maintains | Outperform → Outperform | — | $2.77 | $5.59 | +101.8% | +117.0% | -18.3% | -11.2% | +2.8% | +8.0% |
| May 15 | Needham | Maintains | Buy → Buy | — | $1.81 | $1.85 | +2.2% | +17.7% | -4.7% | -0.5% | +6.9% | -7.4% |
| Apr 8 | Needham | Maintains | Buy → Buy | — | $3.31 | $2.90 | -12.4% | -42.0% | +3.6% | -7.5% | +7.6% | -1.0% |
| Mar 26 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $3.99 | $3.91 | -2.0% | -8.8% | -2.7% | -10.7% | -5.1% | +0.0% |
| Mar 25 | Cantor Fitzgerald | Maintains | Overweight → Overweight | — | $3.91 | $3.87 | -1.0% | +2.0% | -8.8% | -2.7% | -10.7% | -5.1% |
| Mar 25 | Needham | Maintains | Buy → Buy | — | $3.91 | $3.87 | -1.0% | +2.0% | -8.8% | -2.7% | -10.7% | -5.1% |
| Mar 25 | Wedbush | Maintains | Outperform → Outperform | — | $3.91 | $3.87 | -1.0% | +2.0% | -8.8% | -2.7% | -10.7% | -5.1% |
| Nov 13 | Needham | Maintains | Buy → Buy | — | $13.07 | $13.26 | +1.5% | -10.5% | -10.2% | -4.3% | +2.5% | +9.6% |
| Aug 30 | Needham | Maintains | Buy → Buy | — | $11.30 | $10.86 | -3.9% | +2.1% | -4.6% | +3.4% | +4.7% | +0.9% |
| Date | Insider | Title | Type | Shares | Price | Value | Owned After | D1% | D5% |
|---|---|---|---|---|---|---|---|---|---|
| Jul 24, 2026 | RA CAPITAL MANAGEMENT, L.P. | — | Buy | 41,319 | $9.99 | $413K | 17,283,802 | -4.84% | +2.88% |
| Jul 23, 2026 | RA CAPITAL MANAGEMENT, L.P. | — | Buy | 59,880 | $9.96 | $596K | 17,242,483 | -0.99% | +4.09% |
| Jul 22, 2026 | RA CAPITAL MANAGEMENT, L.P. | — | Buy | 84,124 | $9.93 | $835K | 17,182,603 | -0.99% | +4.09% |
| Jul 21, 2026 | RA CAPITAL MANAGEMENT, L.P. | — | Buy | 120,582 | $9.55 | $1.2M | 17,098,479 | -0.99% | +4.09% |
| Jul 17, 2026 | RA CAPITAL MANAGEMENT, L.P. | — | Buy | 7,882 | $8.95 | $71K | 16,977,927 | +9.29% | +2.89% |
| Jul 16, 2026 | RA CAPITAL MANAGEMENT, L.P. | — | Buy | 152,472 | $8.93 | $1.4M | 16,970,045 | +9.29% | +2.89% |
| Jul 13, 2026 | RA CAPITAL MANAGEMENT, L.P. | — | Buy | 6,522 | $8.94 | $58K | 16,817,543 | -0.99% | +4.09% |
| Jul 13, 2026 | RA CAPITAL MANAGEMENT, L.P. | — | Buy | 6,552 | $8.94 | $59K | 16,817,573 | +6.10% | +9.29% |
| Jul 10, 2026 | RA CAPITAL MANAGEMENT, L.P. | — | Buy | 15,102 | $8.97 | $135K | 16,811,021 | +6.10% | +9.29% |
| Jun 26, 2026 | RA CAPITAL MANAGEMENT, L.P. | — | Buy | 1,876 | $8.98 | $17K | 16,795,919 | +1.25% | +0.42% |
| Jun 25, 2026 | RA CAPITAL MANAGEMENT, L.P. | — | Buy | 31,000 | $8.88 | $275K | 16,794,043 | +1.25% | +0.42% |
| Jun 16, 2026 | RA CAPITAL MANAGEMENT, L.P. | — | Buy | 124,893 | $8.89 | $1.1M | 16,763,043 | +11.56% | -4.90% |
| Jun 15, 2026 | RA CAPITAL MANAGEMENT, L.P. | — | Buy | 15,414 | $8.99 | $139K | 16,638,150 | +11.56% | -4.90% |
| Jun 12, 2026 | RA CAPITAL MANAGEMENT, L.P. | — | Buy | 391,019 | $8.57 | $3.4M | 16,622,736 | +11.56% | -4.90% |
| Jun 11, 2026 | RA CAPITAL MANAGEMENT, L.P. | — | Buy | 548,580 | $7.91 | $4.3M | 16,231,717 | +6.75% | -1.21% |
| Jun 10, 2026 | RA CAPITAL MANAGEMENT, L.P. | — | Buy | 103 | $7.00 | $721 | 15,683,137 | +6.75% | -1.21% |
| Jun 9, 2026 | RA CAPITAL MANAGEMENT, L.P. | — | Buy | 479,039 | $6.91 | $3.3M | 15,683,034 | +6.75% | -1.21% |
| May 19, 2026 | Raymon Heather | SVP, Research and Development | Sell | 3,095 | $9.01 | $28K | 148,228 | -8.30% | -0.52% |
| May 19, 2026 | Horan Christopher | Chief Tech Operations Officer | Sell | 7,002 | $9.01 | $63K | 293,450 | -8.30% | -0.52% |
| May 19, 2026 | Aslan Fred | Chief Executive Officer | Sell | 27,116 | $9.01 | $244K | 1,535,082 | -8.30% | -0.52% |
| May 19, 2026 | Bush Jennifer | COO, CLO, Compliance Officer | Sell | 8,790 | $9.01 | $79K | 337,920 | -8.30% | -0.52% |
| May 19, 2026 | Banerjee Subhashis | Chief Medical Officer | Sell | 7,037 | $9.01 | $63K | 144,963 | -8.30% | -0.52% |
| May 11, 2026 | GC Corp. | — | Buy | 347,222 | $11.52 | $4.0M | 1,607,734 | +4.21% | +10.19% |
| May 11, 2026 | GC Corp. | — | Buy | 1,085,069 | $11.52 | $12.5M | 4,391,969 | +4.21% | +10.19% |
| May 11, 2026 | RA CAPITAL MANAGEMENT, L.P. | — | Buy | 6,510,416 | $11.52 | $75.0M | 15,203,995 | +1.71% | -8.30% |
8-K
Artiva Biotherapeutics, Inc. -- 8-K Filing
Artiva Biotherapeutics announced severance terms for an executive including $135,000 in payments and nine months of COBRA continuation coverage, contingent upon standard conditions.
May 19
8-K · 2.02
!! High
Artiva Biotherapeutics, Inc. -- 8-K 2.02: Earnings Results
Artiva Biotherapeutics reported financial results and operational performance, with detailed metrics available in the attached press release for investor evaluation.
May 8
8-K
Unknown — 8-K Filing
Artiva Biotherapeutics expects near-term catalysts—AlloNK clinical data and FDA pivotal trial guidance in H1 2026—that could validate its rheumatoid arthritis strategy and drive significant stock appreciation if successful.
Mar 10
8-K
Artiva Biotherapeutics, Inc. -- 8-K Filing
Artiva Biotherapeutics appointed a new executive with extensive Johnson & Johnson financial leadership experience, including CFO responsibilities, strengthening its senior management team.
Feb 24
8-K
Artiva Biotherapeutics, Inc. -- 8-K Filing
Artiva Biotherapeutics appointed an experienced healthcare strategist with Boston Consulting Group and Galapagos experience to its Scientific Strategy Board, strengthening its advisory capabilities for drug development decisions.
Feb 19
Institutional (13F) — Top 0
All ↗
No 13F holders found.
Mutual Funds / ETFs (N-PORT) — Top 1
All ↗
| # | Fund | Shares | Value | Period |
|---|---|---|---|---|
| 1 | Ultra-Small Company Market Fund | 35,000 | $225K | Mar 2026 |
Valuation
Market Cap
$551.5M
Enterprise Value
$181.7M
P/E (TTM)
—
Forward P/E
—
PEG Ratio
0.04x
P/B
2.51x
P/S
—
P/FCF
-3.55x
EV/EBITDA
—
Shares Out
24.4M
Financials (TTM)
Revenue
$0
Net Income
-$87.1M
EBITDA
-$84.4M
Free Cash Flow
-$79.3M
Op Cash Flow
-$76.8M
EPS Basic
$-3.43
EPS Diluted
$-3.55
EPS Forward
$-3.38
Gross Margin
—
Op Margin
—
Net Margin
—
Balance Sheet
Total Assets
$130.9M
Total Liab.
$21.0M
Total Equity
$110.0M
Cash
$108.0M
LT Debt
$7.9M
Book Value/Sh
$4.50
Debt/Equity
0.10x
Current Ratio
8.61
Quick Ratio
8.61
Returns & Growth
ROE
-76.3%
ROA
-64.0%
ROIC
-74.9%
Rev Growth YoY
-100.0%
EPS Growth YoY
+34.0%
Price Returns
2W
+15.1%
1M
+19.6%
3M
+8.5%
6M
+189.0%
12M
+366.8%
Technicals
52W High
$14.53
52W Low
$2.22
50d MA
$9.51
200d MA
$6.77
RSI (14)
65.50
ATR (14)
$0.89
Beta
1.48
Avg Volume
406K
Dividends
Div Rate
$0.00
Div Yield
—
Frequency
—
Ex-Div Date
—
Analyst Price Targets
Consensus
$20.50
High
$23.00
Low
$18.00
Median
$20.50
Data updated apr 24, 2026 7:04pm
· Source: financialmodelingprep.com